ARDS was underrecognized in the study population across all body mass indexesBMIs, but this underrecognition did not explain why patients with class 3 obesity were more likely to meet ARDS criteria but not receive low tidal volume ventilation.
Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.
Statin therapy before septic shock may decrease the risk for acute respiratory distress syndrome.
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.
The FDA has granted Breakthrough Therapy designation to nintedanib for the treatment of chronic fibrosing ILDs with a progressive phenotype.
Researchers question previous recommendations that demonstrated that prone ventilation reduced mortality in patients with acute respiratory distress syndrome.
Although the planned statistical model could not be applied to primary end point data, key secondary end point analysis suggested that patients with progressive fibrosing unclassifiable interstitial lung disease could benefit from pirfenidone.
Nintedanib was linked to a lower rate of decline in forced vital capacity vs placebo in a phase 3 trial.
Plasma biomarkers of progressive idiopathic pulmonary fibrosis may be markers of progressive pulmonary fibrosis regardless of the type of interstitial lung disease.
Prehospital vulnerability was associated with higher 1-year mortality but not with acute respiratory distress syndrome or short-term mortality.
